David A. Siegel Wave Life Sciences Ltd. Transaction History

Two Sigma Advisers, LP

$47 Billion
Q3 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Wave Life Sciences Ltd. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 251,700 shares of WVE stock, worth $1.74 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

251,700

Previous 92,300 172.7%

Holding current value

$1.74 Million

Previous $599,000 202.84%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$6.66 - $10.15 $1.06 Million - $1.62 Million	159,400 Added 172.7%	251,700 $1.81 Million
Q2 2025 Aug 14, 2025	BUY	$5.48 - $8.1 $343,596 - $507,870	62,700 Added 211.82%	92,300 $599,000
Q1 2025 May 15, 2025	SELL	$8.08 - $13.51 $311,080 - $520,135	-38,500 Reduced 56.53%	29,600 $239,000
Q4 2024 Feb 14, 2025	BUY	$8.0 - $16.44 $544,800 - $1.12 Million	68,100 New	68,100 $842,000
Q2 2024 Aug 14, 2024	SELL	$4.38 - $6.48 $251,412 - $371,952	-57,400 Reduced 66.67%	28,700 $143,000

Q1 2024 May 15, 2024	BUY	$3.54 - $6.84 $304,794 - $588,924	86,100 New	86,100 $531,000
Q4 2021 Feb 14, 2022	SELL	$3.14 - $5.15 $35,482 - $58,195	-11,300 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$4.89 - $7.12 $57,212 - $83,304	-11,700 Reduced 50.87%	11,300 $55,000
Q2 2021 Aug 16, 2021	SELL	$5.65 - $7.47 $75,145 - $99,351	-13,300 Reduced 36.64%	23,000 $153,000
Q1 2021 May 17, 2021	SELL	$5.61 - $12.01 $28,050 - $60,050	-5,000 Reduced 12.11%	36,300 $204,000
Q4 2020 Feb 16, 2021	BUY	$6.99 - $9.26 $288,687 - $382,438	41,300 New	41,300 $325,000

Others Institutions Holding WVE

# of Institutions

214

Shares Held

133M

Call Options Held

1.22M

Put Options Held

616K

View Full List

About Wave Life Sciences Ltd.

Ticker WVE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,820,096
Market Cap $600M
Description
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional pr...

More about WVE

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account